In this randomized controlled trial, among patients with atrial fibrillation requiring anticoagulation therapy, asundexian ...

In this randomized controlled trial, abelacimab led to significantly lower rates of major or clinically relevant nonmajor ...

Discover how botanical and nutrient therapies provided adjunctive support for a 76-year-old patient with treatment-resistant ...

Atrial fibrillation is a cardiac arrhythmia in which the upper chambers of the heart the atria beat irregularly and, often, rapidly. The condition occurs as a consequence of uncoordinated ...

Atrial fibrillation (AF) is the most common sustained arrhythmia worldwide ... The use of preprocedural transesophageal echocardiography to rule out intracardiac thrombus was according to expert ...

Bayer has decided to discontinue a phase 3 trial of its oral Factor XIa inhibitor asundexian in patients with atrial fibrillation ... cancer patients at risk of thrombosis in its MAGNOLIA and ...

Psoriasis is linked to an increased risk of atrial fibrillation (AF). However, data on the electrophysiological substrate and outcomes of AF ablation in patients with psoriasis are lacking. We ...

The FDA approved the first generics of the direct oral anticoagulant rivaroxaban, the agency announced on Tuesday.

The company also received tentative FDA approval for its ANDA for Rivaroxaban, an anticoagulant used to treat deep vein ...

The rise in Biocon share price came after the company announced that its wholly-owned subsidiary, Biocon Pharma, has received ...

The clock is, once again, going ahead by an hour. While "springing forward" might seem easy, it's a good idea to know the ...

Ten projects at Queen’s are receiving support from the Canadian Institutes of Health Research to advance research that will have a high impact on health care knowledge and delivery.